Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Stratifying Diabetes: Desperately Seeking Specificity

  1. Richard David Leslie⇑ and
  2. Samuel Thomas Jerram
  1. Blizard Institute, University of London, London, U.K.
  1. Corresponding author: R.D. Leslie, r.d.g.leslie{at}qmul.ac.uk.
Diabetes 2017 Apr; 66(4): 801-803. https://doi.org/10.2337/dbi16-0074
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

In 1836 William Barret Travis drew his sword and marked a line in the sand. Those willing to stay and defend the Alamo fort were invited to cross the line; in doing so, like Davy Crockett they became immortal, whereas those remaining on the other side of that line were broadly lost to history. Travis was a “splitter.” Physicians, also, tend to be “splitters,” designating individuals with or without disease and subdividing those with disease into groups according to key features (1). Diseases gain identity through clinical phenotype. Only in recent years have we incorporated genetic and nongenetic laboratory-based features into that identity. In doing so, we seek to encapsulate each disease as a categorical entity.

But diabetes has confounded categorization, in part because its key elements are not exclusive to the disease (1–4). Even raised blood glucose is only a proxy for loss of the homeostatic relationship between insulin secretion and insulin sensitivity—a relationship whose tipping point is designated “diabetes” when the risk of retinopathy increases. Initially characterized by the striking clinical phenotype of juvenile-onset diabetes, that classification evolved historically according to therapy (insulin-dependent diabetes) and then immunogenetic features (type 1 diabetes, T1D). The remaining cohort without these characteristic features were designated adult-onset diabetes, non–insulin-dependent diabetes, or, nowadays, type 2 diabetes (T2D). A proportion of apparent T2D patients have the immunogenetic features of T1D and are categorized as latent autoimmune diabetes in adults (LADA) (3,5). These patients with autoimmune adult-onset diabetes have diabetes-associated genes and autoantibodies, notably GAD autoantibodies (GADAb). They tend to show a more aggressive clinical course that often progresses to insulin therapy, have an increased risk of thyroid autoimmunity, and should avoid sulfonylurea therapy (1,5). However, distinguishing autoimmune diabetes from T2D cases is not easy because age at diagnosis, need for insulin treatment, metabolic syndrome, and even the GADAb assay are not categorical biomarkers.

The challenge is to define specific features of adult-onset autoimmune diabetes, and that hunt has encompassed genes, cytokines, chemokines, C-peptide (as a proxy of insulin secretion), and now metabolites. Genetic risk estimates have limited value in T2D and are confounded by the low genetic load in adult T1D (6,7). Cytokine and chemokine analyses found changes not exclusive to any clinical category, showing a graded effect across autoimmune and nonautoimmune diabetes, with an inverse relationship between adaptive and innate immunity, e.g., GADAb titers and serum interleukin-6 levels (8).

In this issue of Diabetes, a group from Scandinavia has sought to categorize adult-onset non–insulin-requiring diabetes by analyzing metabolites (9). Metabolites are small intermediate products of metabolism, including glucose, amino acids, fatty acids, and lactate, and have proved valuable as biomarkers for disease prediction (10–12). Importantly, recent studies identified metabolite changes in both cord blood at birth and the sera of young children before the appearance of diabetes autoantibodies and T1D (13,14). These metabolite changes included persistent decreased levels of proinflammatory lysophosphatidylcholine, most likely acquired prenatally or inherited, with particularly low levels in cord blood if the mother had had a first trimester infection (13).

In the current study, acylcarnitines, both long- and intermediate-chained, showed large differences between diabetes types. Of 13 carnitines, 12 were significantly lower in classic T1D than in both T2D and LADA—changes consistent with an imbalance in lipolysis and Krebs cycle activity (9). However, the metabolite changes were not categorically distinct and had no utility for differentiating LADA from T1D or T2D. Since lipolysis is exquisitely sensitive to insulin, a potential role of insulin (with C-peptide as a proxy) should be considered, and the authors found that plasma C-peptide levels were the strongest determinant of the metabolite profile, with a C-peptide–driven continuum in the metabolite changes across all three clinical diabetes categories, namely, T1D, LADA, and T2D (9). This effect could be anticipated because they had not selected LADA patients by the customary three criteria: adult-onset diabetes, initially non–insulin-requiring, and GADAb positivity. Instead, they substituted—reasonably, in our opinion—the use of insulin therapy with a C-peptide level >0.3 nmol/L, that is, without an absolute insulin deficiency (15). Consequently, the C-peptide levels in LADA were similar to those in T2D. The purity of the cohort for true-positive GADAb is further compromised by the risk of false-positive GADAb in patients with true T2D. The greater the true-positive rate in the screening population for the GADAb assay and the greater the assay specificity, the lower the risk of false positives; for example, here there would have been a false GADAb-positive rate of 2% in the screening population given that the GADAb assay had 98% specificity (14). Nevertheless, those metabolite changes in LADA patients overlapping with the T1D metabolome did identify patients who progressed most rapidly to insulin treatment, despite similar GADAb titers and C-peptide levels (9). In terms of clinical utility, metabolites may yet have a role, and it is worth noting that high levels of both lysophosphatidylcholine and l-carnitine, the opposite of that found in T1D, are risk factors for atherosclerosis (10). Further, both lipid-bound choline, a major epigenetic methyl donor during pregnancy, and l-carnitine can be conflated as important products of the microbiome in early life and could be implicated in diabetes risk (16–18).

The graded loss of C-peptide levels across a range of clinical diabetes phenotypes, highlighted by the current study (9), is a consistent feature of the diabetes state (19). We could look elsewhere for definitive biomarkers to stratify diabetes, but most likely we will resolve the current uncertainty by using combinations of sensitive and specific laboratory biomarkers (12,20) (Fig. 1). In the meanwhile, clinicians should treat the individual before them, using the laboratory only as a diagnostic and therapeutic adjunct. In our current Age of Doubt, looking to emulate General Travis might be unwise; perhaps the best approach is to keep the sword firmly in its sheath.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Collation of predictive features for diabetes endotypes can improve disease prediction because there is an inverse relationship between predictive sensitivity and specificity. As shown here, younger age at onset and absence of metabolic syndrome increases sensitivity for T1D, whereas more diabetes autoantibodies and more C-peptide increases specificity for T1D and T2D, respectively (19).

Article Information

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 806.

  • © 2017 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Leslie RD,
    2. Palmer J,
    3. Schloot NC,
    4. Lernmark A
    . Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 2016;59:13–20pmid:26498592
    OpenUrlPubMed
    1. Halban PA,
    2. Polonsky KS,
    3. Bowden DW, et al
    . β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014;37:1751–1758pmid:24812433
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Tuomi T,
    2. Santoro N,
    3. Caprio S,
    4. Cai M,
    5. Weng J,
    6. Groop L
    . The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014;383:1084–1094pmid:24315621
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 2016;66:241–255
  4. ↵
    1. Hawa MI,
    2. Kolb H,
    3. Schloot N, et al.; Action LADA Consortium
    . Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013;36:908–913pmid:23248199
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Talmud PJ,
    2. Hingorani AD,
    3. Cooper JA, et al
    . Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 2010;340:b4838pmid:20075150
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Howson JM,
    2. Rosinger S,
    3. Smyth DJ,
    4. Boehm BO,
    5. Todd JA; ADBW-END Study Group
    . Genetic analysis of adult-onset autoimmune diabetes. Diabetes 2011;60:2645–2653pmid:21873553
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Schloot NC,
    2. Pham MN,
    3. Hawa MI, et al.; Action LADA Group
    . Inverse relationship between organ-specific autoantibodies and systemic immune mediators in type 1 diabetes and type 2 diabetes: Action LADA 11. Diabetes Care 2016;39:1932–1939pmid:27573939
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Al-Majdoub M,
    2. Ali A,
    3. Storm P,
    4. Rosengren AH,
    5. Groop L,
    6. Spégel P
    . Metabolite profiling of LADA challenges the view of a metabolically distinct subtype. Diabetes 2017;66:806–814pmid:27913577
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Shah SH,
    2. Sun JL,
    3. Stevens RD, et al
    . Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J 2012;163:844–850.e1pmid:22607863
    OpenUrlCrossRefPubMedWeb of Science
    1. Adamski J
    . Key elements of metabolomics in the study of biomarkers of diabetes. Diabetologia 2016;59:2497–2502pmid:27714446
    OpenUrlPubMed
  10. ↵
    1. Suhre K,
    2. Shin SY,
    3. Petersen AK, et al.; CARDIoGRAM
    . Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011;477:54–60pmid:21886157
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. La Torre D,
    2. Seppänen-Laakso T,
    3. Larsson HE, et al.; DiPiS Study Group
    . Decreased cord-blood phospholipids in young age-at-onset type 1 diabetes. Diabetes 2013;62:3951–3956pmid:23929934
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Oresic M,
    2. Simell S,
    3. Sysi-Aho M, et al
    . Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008;205:2975–2984pmid:19075291
    OpenUrlCrossRefPubMed
  13. ↵
    1. Tuomi T,
    2. Carlsson A,
    3. Li H, et al
    . Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150–157pmid:9892237
    OpenUrlAbstract
  14. ↵
    1. Lynch SV,
    2. Pedersen O
    . The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369–2379pmid:27974040
    OpenUrlPubMed
    1. Uusitalo U,
    2. Liu X,
    3. Yang J, et al.; TEDDY Study Group
    . Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr 2016;170:20–28pmid:26552054
    OpenUrlPubMed
  15. ↵
    1. Paul DS,
    2. Teschendorff AE,
    3. Dang MA, et al
    . Increased DNA methylation variability in type 1 diabetes across three immune effector cell types. Nat Commun 2016;7:13555pmid:27898055
    OpenUrlPubMed
  16. ↵
    1. Thunander M,
    2. Törn C,
    3. Petersson C,
    4. Ossiansson B,
    5. Fornander J,
    6. Landin-Olsson M
    . Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. Eur J Endocrinol 2012;166:1021–1029pmid:22436402
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Rose NR
    . Prediction and prevention of autoimmune disease in the 21st century: a review and preview. Am J Epidemiol 2016;183:403–406pmid:26888748
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes: 66 (4)

In this Issue

April 2017, 66(4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Stratifying Diabetes: Desperately Seeking Specificity
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Stratifying Diabetes: Desperately Seeking Specificity
Richard David Leslie, Samuel Thomas Jerram
Diabetes Apr 2017, 66 (4) 801-803; DOI: 10.2337/dbi16-0074

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Stratifying Diabetes: Desperately Seeking Specificity
Richard David Leslie, Samuel Thomas Jerram
Diabetes Apr 2017, 66 (4) 801-803; DOI: 10.2337/dbi16-0074
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.